Intrinsic value of Nuvectra - NVTR

Previous Close

$17.76

  Intrinsic Value

$0.15

stock screener

  Rating & Target

str. sell

-99%

Previous close

$17.76

 
Intrinsic value

$0.15

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of NVTR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  51
  79
  118
  171
  241
  331
  445
  584
  751
  949
  1,178
  1,440
  1,736
  2,066
  2,429
  2,826
  3,255
  3,716
  4,209
  4,732
  5,285
  5,867
  6,478
  7,118
  7,786
  8,483
  9,208
  9,963
  10,748
  11,564
Variable operating expenses, $m
  60
  90
  133
  191
  268
  367
  491
  643
  826
  1,043
  1,290
  1,577
  1,900
  2,261
  2,659
  3,093
  3,563
  4,068
  4,607
  5,179
  5,785
  6,422
  7,091
  7,791
  8,522
  9,285
  10,079
  10,905
  11,765
  12,658
Fixed operating expenses, $m
  37
  38
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  54
  56
  57
  58
  59
  61
  62
  63
  65
  66
  68
  69
Total operating expenses, $m
  97
  128
  171
  230
  308
  408
  533
  686
  870
  1,088
  1,336
  1,624
  1,948
  2,310
  2,709
  3,144
  3,615
  4,121
  4,661
  5,235
  5,842
  6,480
  7,150
  7,852
  8,584
  9,348
  10,144
  10,971
  11,833
  12,727
Operating income, $m
  -46
  -49
  -54
  -59
  -67
  -76
  -88
  -102
  -119
  -138
  -157
  -183
  -212
  -244
  -280
  -318
  -360
  -405
  -452
  -503
  -557
  -613
  -672
  -734
  -798
  -866
  -936
  -1,009
  -1,084
  -1,163
EBITDA, $m
  -40
  -43
  -46
  -51
  -56
  -63
  -71
  -81
  -93
  -107
  -123
  -142
  -162
  -185
  -210
  -237
  -267
  -298
  -332
  -368
  -405
  -445
  -486
  -530
  -575
  -623
  -672
  -723
  -776
  -831
Interest expense (income), $m
  0
  3
  5
  9
  14
  20
  29
  41
  55
  73
  95
  120
  149
  183
  220
  263
  309
  360
  415
  474
  536
  603
  674
  748
  827
  908
  994
  1,083
  1,176
  1,272
  1,372
Earnings before tax, $m
  -48
  -54
  -62
  -73
  -87
  -106
  -129
  -157
  -192
  -233
  -277
  -332
  -395
  -465
  -542
  -627
  -720
  -819
  -926
  -1,040
  -1,160
  -1,287
  -1,421
  -1,561
  -1,707
  -1,859
  -2,019
  -2,184
  -2,356
  -2,535
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -48
  -54
  -62
  -73
  -87
  -106
  -129
  -157
  -192
  -233
  -277
  -332
  -395
  -465
  -542
  -627
  -720
  -819
  -926
  -1,040
  -1,160
  -1,287
  -1,421
  -1,561
  -1,707
  -1,859
  -2,019
  -2,184
  -2,356
  -2,535

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  125
  192
  288
  418
  589
  810
  1,087
  1,427
  1,837
  2,320
  2,881
  3,522
  4,245
  5,051
  5,939
  6,908
  7,958
  9,086
  10,290
  11,569
  12,921
  14,345
  15,839
  17,403
  19,037
  20,740
  22,514
  24,360
  26,279
  28,274
Adjusted assets (=assets-cash), $m
  125
  192
  288
  418
  589
  810
  1,087
  1,427
  1,837
  2,320
  2,881
  3,522
  4,245
  5,051
  5,939
  6,908
  7,958
  9,086
  10,290
  11,569
  12,921
  14,345
  15,839
  17,403
  19,037
  20,740
  22,514
  24,360
  26,279
  28,274
Revenue / Adjusted assets
  0.408
  0.411
  0.410
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
Average production assets, $m
  42
  64
  96
  140
  197
  271
  363
  477
  614
  775
  963
  1,177
  1,419
  1,688
  1,984
  2,308
  2,659
  3,036
  3,438
  3,866
  4,318
  4,793
  5,293
  5,815
  6,361
  6,930
  7,523
  8,140
  8,781
  9,448
Working capital, $m
  3
  4
  6
  9
  12
  17
  22
  29
  38
  47
  59
  72
  87
  103
  121
  141
  163
  186
  210
  237
  264
  293
  324
  356
  389
  424
  460
  498
  537
  578
Total debt, $m
  52
  88
  140
  210
  302
  421
  570
  754
  974
  1,235
  1,537
  1,883
  2,273
  2,707
  3,186
  3,708
  4,274
  4,882
  5,531
  6,220
  6,949
  7,716
  8,522
  9,365
  10,245
  11,163
  12,120
  13,114
  14,149
  15,224
Total liabilities, $m
  67
  104
  155
  225
  318
  436
  586
  769
  990
  1,250
  1,553
  1,898
  2,288
  2,722
  3,201
  3,724
  4,289
  4,897
  5,546
  6,236
  6,964
  7,732
  8,537
  9,380
  10,261
  11,179
  12,135
  13,130
  14,164
  15,240
Total equity, $m
  57
  89
  133
  192
  272
  373
  501
  658
  847
  1,069
  1,328
  1,624
  1,957
  2,328
  2,738
  3,185
  3,669
  4,188
  4,744
  5,333
  5,957
  6,613
  7,302
  8,023
  8,776
  9,561
  10,379
  11,230
  12,115
  13,034
Total liabilities and equity, $m
  124
  193
  288
  417
  590
  809
  1,087
  1,427
  1,837
  2,319
  2,881
  3,522
  4,245
  5,050
  5,939
  6,909
  7,958
  9,085
  10,290
  11,569
  12,921
  14,345
  15,839
  17,403
  19,037
  20,740
  22,514
  24,360
  26,279
  28,274
Debt-to-equity ratio
  0.900
  0.990
  1.050
  1.090
  1.110
  1.130
  1.140
  1.150
  1.150
  1.150
  1.160
  1.160
  1.160
  1.160
  1.160
  1.160
  1.160
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
  1.170
Adjusted equity ratio
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461
  0.461

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -48
  -54
  -62
  -73
  -87
  -106
  -129
  -157
  -192
  -233
  -277
  -332
  -395
  -465
  -542
  -627
  -720
  -819
  -926
  -1,040
  -1,160
  -1,287
  -1,421
  -1,561
  -1,707
  -1,859
  -2,019
  -2,184
  -2,356
  -2,535
Depreciation, amort., depletion, $m
  5
  6
  7
  9
  11
  13
  17
  21
  25
  31
  34
  41
  50
  59
  70
  81
  93
  107
  121
  136
  151
  168
  186
  204
  223
  243
  264
  286
  308
  331
Funds from operations, $m
  -43
  -48
  -55
  -64
  -76
  -92
  -112
  -137
  -166
  -202
  -243
  -291
  -345
  -405
  -473
  -546
  -626
  -713
  -805
  -904
  -1,009
  -1,119
  -1,235
  -1,356
  -1,484
  -1,616
  -1,755
  -1,899
  -2,048
  -2,204
Change in working capital, $m
  1
  1
  2
  3
  4
  5
  6
  7
  8
  10
  11
  13
  15
  16
  18
  20
  21
  23
  25
  26
  28
  29
  31
  32
  33
  35
  36
  38
  39
  41
Cash from operations, $m
  -44
  -49
  -57
  -67
  -80
  -97
  -118
  -144
  -175
  -212
  -255
  -304
  -360
  -422
  -491
  -566
  -648
  -736
  -830
  -930
  -1,036
  -1,148
  -1,265
  -1,388
  -1,517
  -1,651
  -1,791
  -1,936
  -2,087
  -2,245
Maintenance CAPEX, $m
  -1
  -1
  -2
  -3
  -5
  -7
  -9
  -13
  -17
  -22
  -27
  -34
  -41
  -50
  -59
  -70
  -81
  -93
  -107
  -121
  -136
  -151
  -168
  -186
  -204
  -223
  -243
  -264
  -286
  -308
New CAPEX, $m
  -15
  -23
  -32
  -43
  -57
  -74
  -93
  -114
  -137
  -161
  -187
  -214
  -242
  -269
  -297
  -324
  -351
  -377
  -402
  -427
  -452
  -476
  -499
  -523
  -546
  -569
  -593
  -617
  -641
  -667
Cash from investing activities, $m
  -16
  -24
  -34
  -46
  -62
  -81
  -102
  -127
  -154
  -183
  -214
  -248
  -283
  -319
  -356
  -394
  -432
  -470
  -509
  -548
  -588
  -627
  -667
  -709
  -750
  -792
  -836
  -881
  -927
  -975
Free cash flow, $m
  -60
  -73
  -91
  -113
  -142
  -177
  -220
  -270
  -328
  -395
  -469
  -552
  -643
  -741
  -847
  -960
  -1,079
  -1,206
  -1,339
  -1,478
  -1,624
  -1,775
  -1,933
  -2,097
  -2,267
  -2,444
  -2,627
  -2,817
  -3,014
  -3,219
Issuance/(repayment) of debt, $m
  25
  37
  51
  70
  92
  119
  149
  183
  221
  260
  302
  346
  390
  434
  479
  523
  566
  608
  649
  689
  729
  767
  805
  843
  881
  918
  956
  995
  1,034
  1,075
Issuance/(repurchase) of shares, $m
  70
  85
  106
  133
  166
  207
  257
  314
  381
  456
  536
  628
  728
  836
  952
  1,074
  1,203
  1,339
  1,481
  1,629
  1,783
  1,943
  2,109
  2,282
  2,460
  2,645
  2,836
  3,035
  3,241
  3,455
Cash from financing (excl. dividends), $m  
  95
  122
  157
  203
  258
  326
  406
  497
  602
  716
  838
  974
  1,118
  1,270
  1,431
  1,597
  1,769
  1,947
  2,130
  2,318
  2,512
  2,710
  2,914
  3,125
  3,341
  3,563
  3,792
  4,030
  4,275
  4,530
Total cash flow (excl. dividends), $m
  35
  49
  67
  89
  117
  149
  186
  228
  273
  321
  369
  421
  475
  529
  584
  637
  690
  741
  791
  840
  888
  936
  982
  1,028
  1,073
  1,119
  1,166
  1,213
  1,261
  1,311
Retained Cash Flow (-), $m
  -70
  -85
  -106
  -133
  -166
  -207
  -257
  -314
  -381
  -456
  -536
  -628
  -728
  -836
  -952
  -1,074
  -1,203
  -1,339
  -1,481
  -1,629
  -1,783
  -1,943
  -2,109
  -2,282
  -2,460
  -2,645
  -2,836
  -3,035
  -3,241
  -3,455
Prev. year cash balance distribution, $m
  12
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -23
  -37
  -39
  -44
  -50
  -58
  -70
  -87
  -108
  -134
  -167
  -206
  -253
  -307
  -368
  -437
  -514
  -598
  -690
  -789
  -895
  -1,008
  -1,128
  -1,254
  -1,386
  -1,525
  -1,671
  -1,822
  -1,980
  -2,144
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -22
  -34
  -34
  -36
  -38
  -42
  -48
  -54
  -62
  -70
  -79
  -88
  -96
  -103
  -108
  -111
  -112
  -110
  -106
  -100
  -93
  -84
  -74
  -64
  -54
  -45
  -36
  -28
  -22
  -16
Current shareholders' claim on cash, %
  73.2
  57.0
  46.5
  39.0
  33.5
  29.3
  25.9
  23.1
  20.8
  18.9
  17.3
  15.8
  14.6
  13.5
  12.5
  11.7
  10.9
  10.2
  9.5
  8.9
  8.4
  7.9
  7.5
  7.0
  6.7
  6.3
  6.0
  5.6
  5.4
  5.1

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).

FINANCIAL RATIOS  of  Nuvectra (NVTR)

Valuation Ratios
P/E Ratio -4.8
Price to Sales 14.1
Price to Book 2.1
Price to Tangible Book
Price to Cash Flow -7
Price to Free Cash Flow -7
Growth Rates
Sales Growth Rate 160%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 15.7%
Total Debt to Equity 15.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -46.3%
Ret/ On Assets - 3 Yr. Avg. -47.7%
Return On Total Capital -53.9%
Ret/ On T. Cap. - 3 Yr. Avg. -53.2%
Return On Equity -59.8%
Return On Equity - 3 Yr. Avg. -55.2%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 46.2%
Gross Margin - 3 Yr. Avg. 45.4%
EBITDA Margin -276.9%
EBITDA Margin - 3 Yr. Avg. -412.3%
Operating Margin -284.6%
Oper. Margin - 3 Yr. Avg. -436.5%
Pre-Tax Margin -292.3%
Pre-Tax Margin - 3 Yr. Avg. -432.4%
Net Profit Margin -292.3%
Net Profit Margin - 3 Yr. Avg. -432.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

NVTR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NVTR stock intrinsic value calculation we used $31.836 million for the last fiscal year's total revenue generated by Nuvectra. The default revenue input number comes from 0001 income statement of Nuvectra. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NVTR stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NVTR is calculated based on our internal credit rating of Nuvectra, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Nuvectra.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NVTR stock the variable cost ratio is equal to 121.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $36 million in the base year in the intrinsic value calculation for NVTR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.7% for Nuvectra.

Corporate tax rate of 27% is the nominal tax rate for Nuvectra. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NVTR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NVTR are equal to 81.7%.

Life of production assets of 28.5 years is the average useful life of capital assets used in Nuvectra operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NVTR is equal to 5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $48.173 million for Nuvectra - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 14.26 million for Nuvectra is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Nuvectra at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
NVRO Nevro 39.23 2.07  str.sell
PEN Penumbra 129.93 2.68  str.sell
BSX Boston Scienti 36.21 12.09  str.sell
IART Integra LifeSc 52.52 59.90  hold
NURO NeuroMetrix 1.000 0.17  str.sell

COMPANY NEWS

▶ Nuvectra: 3Q Earnings Snapshot   [04:41PM  Associated Press]
▶ Nuvectra® Announces Pricing of Follow-On Stock Offering   [Sep-11-18 10:09PM  GlobeNewswire]
▶ Nuvectra: 2Q Earnings Snapshot   [04:53PM  Associated Press]
▶ Nuvectra Added to the Russell 2000® Index   [Jun-25-18 08:01AM  GlobeNewswire]
▶ Nuvectra to Present at Two Upcoming Investor Conferences   [May-17-18 08:30AM  GlobeNewswire]
▶ Nuvectra: 1Q Earnings Snapshot   [May-02-18 05:44PM  Associated Press]
▶ Nuvectra reports 4Q loss   [Mar-06-18 04:55PM  Associated Press]
▶ Nuvectra Corp. to Host Earnings Call   [12:15PM  ACCESSWIRE]
▶ Nuvectra to Present at Two Upcoming Investor Conferences   [Feb-27-18 08:30AM  GlobeNewswire]
▶ Nuvectra Announces Pricing of Follow-On Stock Offering   [Feb-01-18 09:00AM  GlobeNewswire]
▶ Nuvectra Announces Proposed Follow-On Stock Offering   [Jan-31-18 04:01PM  GlobeNewswire]
▶ How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?   [Jan-10-18 07:02AM  Simply Wall St.]
▶ Nuvectra Announces Analyst & Investor Meeting at NANS 2018   [Jan-03-18 04:01PM  GlobeNewswire]
▶ ETFs with exposure to Nuvectra Corp. : December 21, 2017   [Dec-21-17 11:40AM  Capital Cube]
▶ ETFs with exposure to Nuvectra Corp. : November 17, 2017   [Nov-17-17 12:36PM  Capital Cube]
▶ Nuvectra reports 3Q loss   [Nov-01-17 05:35PM  Associated Press]
▶ ETFs with exposure to Nuvectra Corp. : October 27, 2017   [Oct-27-17 11:08AM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.